CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops novel class of antibody therapeutics based on its Probody technology platform that address clinically-validated cancer targets in immuno-oncology, such as PD-L1, as well as novel targets, comprising CD-166. In addition it has strategic collaborations with Bristol-Myers Squibb Company, Pfizer Inc., and ImmunoGen, Inc. to develop selected Probody therapeutics. The company was founded in 2008 and is headquartered in South San Francisco, California.